MedPath

Body Composition and Fatty Liver Disease

Not Applicable
Active, not recruiting
Conditions
Fatty Liver
Registration Number
NCT05695118
Lead Sponsor
Seoul National University Hospital
Brief Summary

This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • metabolic dysfunction-associated fatty liver disease (fatty liver with overweight/obesity, or type II DM or other metabolic dysfunction)
  • or non-alcoholic fatty liver disease with liver function test abnormality
  • signed informed consent
Exclusion Criteria
  • chronic hepatitis B or C
  • other disease related to fatty liver such as glycogen storage disease, lipodystrophy, familial combined hyperlipidemia, hypobetalipoproteinemia, Weber-Christian syndrome or abetalipoproteinemia
  • on medication related to hepatic steatosis (tamoxifen, steroid, valproic acid, methotrexate, amiodarone)
  • diabetes after pancreatectomy
  • history of total parenteral nutrition in 6 months
  • pregnancy or nursing mother

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
relationship between body composition analysis result from CT and liver fat fraction6 month after CT acquisition

relationship between visceral fat volume fraction (obtained from CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and CAP value of fibroscan

Secondary Outcome Measures
NameTimeMethod
ratio of appropriate non-contrast low dose abdomen CT acquisition & analysis6 month after CT acquisition

Number of CT scan with effective dose \< 1.5 mSv AND successful automatic body composition analysis (without manual editing) divided by total number of CT scan

relationship between body composition analysis result from CT and hepatic fibrosis6 month after CT acquisition

relationship between visceral fat volume fraction (CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and liver stiffness value of fibroscan

agreement between body composition analysis result from CT and bioelectrical impedance analysis (Inbody test)6 month after CT acquisition

agreement of visceral fat, subcutaneous fat, muscle amount between CT based body composition and Inbody test results

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.